Grifols Annual Report on Form 20-F for 2011 Filed with SEC on March 29, 2012

^{Published on 2012-03-30 08:12:11 - Market Wire}
 

Grifols Annual Report on Form 20-F for 2011 Filed with SEC on... -- BARCELONA, Spain, March 30, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about GRFS

BARCELONA, Spain, March 30, 2012 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE:GRF, MCE:GRF.P and NASDAQ: [ GRFS ]), announced that it has filed its 2011 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on March 29, 2012.  Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2011.

(Logo:  [ http://photos.prnewswire.com/prnh/20110304/PH59473LOGO ] )

Form 20-F can be accessed electronically through the Grifols website at [ http://inversores.grifols.com/portal/es/grifols/sec_filings ]. The Form 20-F is also available on the SEC's website at [ http://www.sec.gov ].

Grifols will deliver, within a reasonable time after request, a hard copy of the Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request. To request a hard copy, shareholders may contact Grifols by email at [ investors@grifols.com ]to the attention of Grifols's Investor Relations, Re: 2011 Annual Report on Form 20-F.

About Grifols

Grifols is a Spanish group, specializing in the hospital-pharmaceutical sector, and with a presence in over 100 countries. Since 2006, Grifols ordinary (Class A) shares have been listed on the Spanish Continuous Market and it has been included in the Ibex-35 (GRF) since 2008. Since 2011, non-voting Grifols shares (Class B) have also been listed on the Spanish Continuous Market (GRF.P) and on the NASDAQ (GRFS) via ADRs (American Depositary Receipts).

Grifols today is the world's third largest producer of plasma derivatives by capacity and is the sector's largest European company, with a balanced and diverse range of products. The group will strengthen its position within the industry as a vertically integrated company, on the basis of its completed and additional planned investments. In terms of raw material, Grifols is the leading plasma collection company, with supplies assured via its network of 147 plasmapheresis centers in the United States, while its production plants in Spain and the United States ensure that it has the fractionation capacity to satisfy rising demand. Geographic diversification is one of the key elements of the group's strategy for growth, and it has a major presence in the United States, Canada and Europe.

SOURCE Grifols S.A.